Pharmafile Logo

Medscape Education Wins SILVER for Rare Disease Campaign

July 24, 2025 | Silver Award, rare disease 

- PMLiVE

We are thrilled to announce that Medscape Education has been honored with the SILVER Award in the Patient Education Information division category by the 2025 National Health Information Awards! This recognition highlights the powerful impact of our campaign, “Shortening the Journey for Patients with a Rare Disease,” and affirms our commitment to advancing healthcare education.

Every day, over 300 million people around the world live with a rare disease, many waiting years for a diagnosis. In February 2024, we launched Shorten the Journey, a month-long digital initiative culminating on Rare Disease Day (February 29). The campaign combined compelling patient stories, precision-targeted outreach, and free, accredited education to empower clinicians to recognize and diagnose rare conditions faster.

And the results* were extraordinary:

  • 462% increase in traffic to our Pathways in Rare Disease learning center 
  • 53% boost in engagement with our rare disease education  
  • Over 46,000 unique learners engaged in rare disease education, with 60% reached through social media 

Since its launch in 2021, Pathways in Rare Disease has engaged 1.5 million healthcare professionals, with patient voices at the core of every activity.. We are proud of the momentum we have built, and our ongoing commitment to improving rare disease diagnosis and care. 

Looking ahead, we are accelerating our impact: expanding global access, leveraging new technologies, and fostering partnerships to further shorten the diagnostic journey for millions worldwide.

*Source: Medscape Internal Use Data. Feb 2024

This content was provided by Medscape Education

Company Details

 Latest Content from  Medscape Education 

Showing Deep Expertise at ONS

The Medscape Oncology team will be connecting with the oncology nursing community this week in Washington, DC for the ONS Congress 2024.  Medscape Oncology has deep expertise in the oncology...

MEDSCAPE’S NEW AGE OF CERTAINTY FOR CME

The CME industry is changing. More than ever, activities need to be prioritized and measured to increase their impact on patient outcomes. Improving patient outcomes is the core objective for...

Getting Past the Old-Fashioned View of Patient Advocacy

Patient advocacy organizations today are data-driven, doing amazing work — and have the hard evidence to support their impact on patient care. The challenge is getting past the perception of...

Mile High Impact at AAN 2024

The Medscape team will be joining our neurology colleagues in Denver, CO for this year’s AAN Annual Meeting. Impact will take center stage at this year’s event as Medscape presents...

Everything Was Peachy at ACC 2024 in Atlanta, GA

The annual ACC meeting has officially wrapped up in Atlanta, bringing a successful conference to a close for another year.  During the conference, members of the Medscape team hosted a...

A Woman Should Not Be Treated As a Small Man

What should the future of women’s healthcare look like? Two renowned physicians say it involves a multidisciplinary, holistic approach, where a group of different specialists work together to provide a...

Sharing Four Times the Impact at ACC 2024

ACC is kicking off next week in Atlanta, GA, and Medscape is heading south to join our cardiology colleagues. The Medscape team will be hosting booth #3431 on the exhibit...

Transforming San Diego for AAD 2024

The 2024 meeting of the American Academy of Dermatology has wrapped up, and Medscape has returned from a series of successful days at their booth, symposia, and offsite event. To...

The Power Dynamics of Women and Cancer

Women, Power, and Cancer: a Lancet commission, studied the interaction of women and cancer through a social justice and equity lens. What does ‘power’ mean when it comes to cancer...

Evaluating the Forces Shaping Women’s Healthcare

Gaps in women’s healthcare go beyond access and cost. Do clinicians have the tools they need to understand women’s health?